• Explore /
  • Poster
  • / Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Abstract Poster

Authors

null

Scott G. Williams

Peter MacCallum Cancer Centre, East Melbourne, Australia

Scott G. Williams , Ian D. Davis , Christopher Sweeney , Martin R. Stockler , Andrew James Martin , Wendy Hague , Xanthi Coskinas , Sonia Yip , Emily Tu , Howard Chan , Nicola Jane Lawrence , Ray McDermott , Simon Hughes , Vittorio Marchesin , Olwyn Deignan , Paul L. Nguyen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT02446444

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS5086)

DOI

10.1200/JCO.2016.34.15_suppl.TPS5086

Abstract #

TPS5086

Poster Bd #

436b

Abstract Disclosures

Similar Posters

First Author: Scott Williams

First Author: Scott Williams

First Author: Scott G. Williams

Poster

2021 Genitourinary Cancers Symposium

<em>SPOP</em> mutations in prostate cancer: Clinical and genomic features.

SPOP mutations in prostate cancer: Clinical and genomic features.

First Author: Mari Nakazawa